Video Experimental Relacionado

Updated: Jan 14, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

La USP3 promueve la progresión del glioma al estabilizar la PLK1 mediante desubiquitinación

Feng Yan^1,2,3, Yongzhi Shan^1,2,3, Yaming Wang^1,2,3

¹Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China.

Aging and disease

|January 12, 2026

Resumen

La enzima desubiquitinante USP3 estabiliza la PLK1, promoviendo la progresión y malignidad del glioma. Dirigirse al eje USP3-PLK1 ofrece una estrategia terapéutica potencial para tumores cerebrales agresivos.

Área de la Ciencia:

Oncología
Biología Molecular
Bioquímica

Sus antecedentes:

El glioma es un tumor cerebral agresivo que exige nuevos objetivos terapéuticos.
Las vías de ubiquitina y desubiquitina son cruciales en la progresión del cáncer.
La USP3 (enzima desubiquitinante) y la PLK1 (quinasa del ciclo celular) están implicadas en la proliferación del cáncer.

Objetivo del estudio:

Investigar si la USP3 modula la PLK1 a través de la desubiquitinación, influyendo en la progresión del glioma.
Analizar la expresión de USP3 en tejidos de glioma.
Determinar el vínculo mecanicista entre USP3, PLK1 y la malignidad del glioma.

Principales métodos:

Conjuntos de datos TCGA para el análisis de la expresión de USP3.
Modelos celulares de ganancia de función (sobreexpresión de USP3) y pérdida de función (reducción de USP3).
Ensayos de proliferación celular (CCK-8), ciclo celular (citometría de flujo), migración/invasión (Transwell).
Xenoinjertos de ratones desnudos e inmunohistoquímica de PCNA.
Co-inmunoprecipitación y Western blot para evaluar las interacciones proteicas y la ubiquitina.

Principales resultados:

La USP3 se sobreexpresó en tejidos de glioma.
La sobreexpresión de USP3 aumentó la proliferación, la progresión del ciclo celular y la invasión de las células de glioma.
La reducción de USP3 suprimió estos fenotipos malignos.
La USP3 desubiquitina y estabiliza la PLK1 reduciendo la ubiquitina K48-ligada.
La reducción de USP3 aumentó la ubiquitina de PLK1 y disminuyó la abundancia de PLK1.
Los xenoinjertos tumorales mostraron un aumento del crecimiento y los niveles de PCNA con la sobreexpresión de USP3, y una reducción del crecimiento con la reducción de USP3.

Conclusiones:

La USP3 promueve la malignidad del glioma al desubiquitinar y estabilizar la PLK1.
Esta estabilización mejora la proliferación y la invasión de las células de glioma.
El eje USP3-PLK1 representa un objetivo terapéutico potencial para el tratamiento del glioma.

Palabras clave:

USP3 PLK1 glioma desubiquitinación estabilización de proteínas proliferación celular invasión celular terapia contra el cáncer

Más Videos Relacionados

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Videos de Conceptos Relacionados

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...